Cargando…

Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma

During recent years considerable progress has been made in the treatment of multiple myeloma. However, despite the current improvements in the prognosis of this malignancy, it always ends with relapse, and therefore new therapy approaches for destroying resistant cancer cells are needed. Presently,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jasiński, Marcin, Basak, Grzegorz W., Jedrzejczak, Wiesław W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943463/ https://www.ncbi.nlm.nih.gov/pubmed/33717171 http://dx.doi.org/10.3389/fimmu.2021.632937

Ejemplares similares

The Role of the Crosstalk Between Gut Microbiota and Immune Cells in the Pathogenesis and Treatment of Multiple Myeloma
por: Jasiński, Marcin, et al.
Publicado: (2022)

Next generations of CAR-T cells - new therapeutic opportunities in hematology?
por: Tomasik, Jaromir, et al.
Publicado: (2022)

Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma
por: Du, Mengyi, et al.
Publicado: (2022)

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
por: Zhang, Xiaomin, et al.
Publicado: (2023)

Road testing new CAR design strategies in multiple myeloma
por: Rana, Priyanka S., et al.
Publicado: (2022)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Ice-cream used as cryotherapy during high-dose melphalan conditioning reduces oral mucositis after autologous hematopoietic stem cell transplantation
por: Jasiński, Marcin, et al.
Publicado: (2021)

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Epidemiology of multiple myeloma in Poland in the years 2008–2017
por: Waszczuk-Gajda, Anna, et al.
Publicado: (2020)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
por: Alabanza, Leah M., et al.
Publicado: (2022)

Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
por: Xia, Yuan, et al.
Publicado: (2023)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
por: Deng, Haobin, et al.
Publicado: (2021)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias
por: Jasiński, Marcin, et al.
Publicado: (2021)

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma
por: Duan, Deming, et al.
Publicado: (2021)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Immunotherapy for the treatment of multiple myeloma
por: Boussi, Leora S., et al.
Publicado: (2022)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
por: Wang, Xue, et al.
Publicado: (2022)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

The Role of Fecal Microbiota Transplantation in the Treatment of Acute Graft-versus-Host Disease
por: Biliński, Jarosław, et al.
Publicado: (2022)

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
por: Que, Yimei, et al.
Publicado: (2021)

A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
por: Liu, Yang, et al.
Publicado: (2023)

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
por: Gahrton, Gösta
Publicado: (2023)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
por: Rodríguez-Otero, Paula, et al.
Publicado: (2020)

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
por: Bannas, Peter, et al.
Publicado: (2018)

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil
por: Hungria, Vania, et al.
Publicado: (2023)

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
por: Li, Hongwen, et al.
Publicado: (2023)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
por: Hu, Chunmei, et al.
Publicado: (2023)

Cytokines in CAR T Cell–Associated Neurotoxicity
por: Gust, Juliane, et al.
Publicado: (2020)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells
por: Cooke, Rachel Elizabeth, et al.
Publicado: (2020)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2020)

New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma
por: McClanahan, Alli, et al.
Publicado: (2022)

Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Natural Killer Cells in the Malignant Niche of Multiple Myeloma
por: Venglar, Ondrej, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mg3ho7fdvrm8qq3doulrdvfe8t